The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Real-world data indicated ART with DTG+3TC was effective and well tolerated among patients with HIV infection regardless of prior ART exposure.

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

Long-acting injectable HIV treatment leads to rectal shedding in a small proportion of patients with HIV, independent of the oral lead-in phase.

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV ...

HIV infections (human immunodeficiency virus infections) include the spectrum of infections caused by the virus HIV that range from asymptomatic seropositivity to acquired immunodeficiency ...

Early diagnosis is vital for HIV. The sooner you receive a blood test and diagnosis, the sooner you can start treatment to bring and keep HIV at undetectable levels. Staying in close contact with ...

he’s been treated with a cocktail of four prescription medications that would cost him $10,000 per month if not for the drug companies’ discount programs. Levy said that among HIV patients ...

The Trump administration is now tearing down that legacy. It has cut funding and programs for HIV research, treatment, and prevention so deeply that “we’re watching the field burn to the ...